176 related articles for article (PubMed ID: 38422463)
1. Trends in Anticoagulant Utilization and Clinical Outcomes for Cancer-Associated Thrombosis: A Multicenter Cohort Study in Thailand's Upper-Middle-Income Country Setting.
Kengkla K; Nathisuwan S; Sripakdee W; Saelue P; Sengnoo K; Sookprasert A; Subongkot S
JCO Glob Oncol; 2024 Feb; 10():e2300353. PubMed ID: 38422463
[TBL] [Abstract][Full Text] [Related]
2. Comparative Effectiveness of Anticoagulants in Patients With Cancer-Associated Thrombosis.
Riaz IB; Fuentes H; Deng Y; Naqvi SAA; Yao X; Sangaralingham LR; Houghton DE; Padrnos LJ; Shamoun FE; Wysokinski WE; McBane RD
JAMA Netw Open; 2023 Jul; 6(7):e2325283. PubMed ID: 37486628
[TBL] [Abstract][Full Text] [Related]
3. Overall survival with warfarin vs. low-molecular-weight heparin in cancer-associated thrombosis.
Chiasakul T; Redd R; Patell R; Khan AM; McCarthy EP; Neuberg D; Zwicker JI
J Thromb Haemost; 2021 Nov; 19(11):2825-2834. PubMed ID: 34490999
[TBL] [Abstract][Full Text] [Related]
4. Transition of management strategies and long-term outcomes in cancer-associated venous thromboembolism from the warfarin era to the direct oral anticoagulant era.
Chatani R; Yamashita Y; Morimoto T; Kaneda K; Mushiake K; Kadota K; Nishimoto Y; Ikeda N; Kobayashi Y; Ikeda S; Kim K; Inoko M; Takase T; Tsuji S; Oi M; Kimura T;
Eur J Intern Med; 2024 May; 123():72-80. PubMed ID: 38278660
[TBL] [Abstract][Full Text] [Related]
5. Impact of anticoagulant choice on hospitalized bleeding risk when treating cancer-associated venous thromboembolism.
Zakai NA; Walker RF; MacLehose RF; Adam TJ; Alonso A; Lutsey PL
J Thromb Haemost; 2018 Dec; 16(12):2403-2412. PubMed ID: 30240508
[TBL] [Abstract][Full Text] [Related]
6. Efficacy and safety of direct oral anticoagulants versus low-molecular-weight heparin for thromboprophylaxis after cancer surgery: a systematic review and meta-analysis.
Zhou H; Chen TT; Ye LL; Ma JJ; Zhang JH
World J Surg Oncol; 2024 Feb; 22(1):69. PubMed ID: 38403630
[TBL] [Abstract][Full Text] [Related]
7. Anticoagulation for the long-term treatment of venous thromboembolism in people with cancer.
Kahale LA; Hakoum MB; Tsolakian IG; Matar CF; Terrenato I; Sperati F; Barba M; Yosuico VE; Schünemann H; Akl EA
Cochrane Database Syst Rev; 2018 Jun; 6(6):CD006650. PubMed ID: 29920657
[TBL] [Abstract][Full Text] [Related]
8. Direct Oral Anticoagulants vs Low-Molecular-Weight Heparin and Recurrent VTE in Patients With Cancer: A Randomized Clinical Trial.
Schrag D; Uno H; Rosovsky R; Rutherford C; Sanfilippo K; Villano JL; Drescher M; Jayaram N; Holmes C; Feldman L; Zattra O; Farrar-Muir H; Cronin C; Basch E; Weiss A; Connors JM;
JAMA; 2023 Jun; 329(22):1924-1933. PubMed ID: 37266947
[TBL] [Abstract][Full Text] [Related]
9. Comparison Between Non-vitamin K Antagonist Oral Anticoagulants and Low-Molecular-Weight Heparin in Asian Individuals With Cancer-Associated Venous Thromboembolism.
Chen DY; Tseng CN; Hsieh MJ; Lan WC; Chuang CK; Pang ST; Chen SW; Chen TH; Chang SH; Hsieh IC; Chu PH; Wen MS; Chen JS; Chang JW; See LC; Huang WK
JAMA Netw Open; 2021 Feb; 4(2):e2036304. PubMed ID: 33533929
[TBL] [Abstract][Full Text] [Related]
10. Effectiveness and Safety of Apixaban, Low-Molecular-Weight Heparin, and Warfarin among Venous Thromboembolism Patients with Active Cancer: A U.S. Claims Data Analysis.
Cohen A; Keshishian A; Lee T; Wygant G; Rosenblatt L; Hlavacek P; Mardekian J; Wiederkehr D; Sah J; Luo X
Thromb Haemost; 2021 Mar; 121(3):383-395. PubMed ID: 33171521
[TBL] [Abstract][Full Text] [Related]
11. Efficacy and Safety of Direct Oral Anticoagulants in Venous Thromboembolism Compared to Traditional Anticoagulants in Morbidly Obese Patients: A Systematic Review and Meta-Analysis.
Katel A; Aryal M; Neupane A; Gosain R; Pathak R; Bhandari Y; Kouides P
Cureus; 2021 Apr; 13(4):e14572. PubMed ID: 34026385
[TBL] [Abstract][Full Text] [Related]
12. Assessment of venous thromboembolism treatment in patients with cancer on low molecular weight heparin, warfarin, and the direct oral anticoagulants.
Uppuluri EM; Burke KR; Haaf CM; Shapiro NL
J Oncol Pharm Pract; 2019 Mar; 25(2):261-268. PubMed ID: 28942721
[TBL] [Abstract][Full Text] [Related]
13. Trajectories of Oral Anticoagulation Adherence and Associated Clinical Outcomes During Long-Term Anticoagulation Among Medicare Beneficiaries With Venous Thromboembolism.
Park H; Jones BL; Huang PL; Kang HR; Dietrich EA; DeRemer CE; Lo-Ciganic WH
Ann Pharmacother; 2023 Dec; 57(12):1349-1360. PubMed ID: 36999519
[TBL] [Abstract][Full Text] [Related]
14. Clinical Outcomes of Direct Oral Anticoagulants vs Warfarin for Extended Treatment of Venous Thromboembolism.
Fang MC; Reynolds K; Fan D; Prasad PA; Sung SH; Portugal C; Garcia E; Go AS
JAMA Netw Open; 2023 Aug; 6(8):e2328033. PubMed ID: 37581888
[TBL] [Abstract][Full Text] [Related]
15. OC-13 - Safe and effective use of direct oral anticoagulants (DOAC) versus conventional anticoagulation for the treatment of cancer-related venous thromboembolism.
Ross JA; Miller M; Hernandez CR
Thromb Res; 2016 Apr; 140 Suppl 1():S173-4. PubMed ID: 27161685
[TBL] [Abstract][Full Text] [Related]
16. Comparative Effectiveness and Safety of Direct-acting Oral Anticoagulants and Warfarin in Patients with Venous Thromboembolism and Active Cancer: An Observational Analysis.
Dawwas GK; Dietrich E; Smith SM; Davis K; Park H
Clin Ther; 2020 Sep; 42(9):e161-e176. PubMed ID: 32768247
[TBL] [Abstract][Full Text] [Related]
17. Cabozantinib Safety With Different Anticoagulants in Patients With Renal Cell Carcinoma.
Shayeb AM; McManus HD; Urman D; Jani C; Zhang T; Dizman N; Meza L; Sivakumar A; Gan CL; Barata P; Bilen MA; Gao X; Heng D; Pal S; Narra R; Kilari D; Kaymakcalan MD; McGregor B; Choueiri TK; McKay RR
Clin Genitourin Cancer; 2023 Feb; 21(1):55-62. PubMed ID: 36411184
[TBL] [Abstract][Full Text] [Related]
18. Effectiveness and safety of direct oral anticoagulants in patients with cancer associated venous thromboembolism.
Douros A; Filliter C; Azoulay L; Tagalakis V
Thromb Res; 2021 Jun; 202():128-133. PubMed ID: 33836492
[TBL] [Abstract][Full Text] [Related]
19. Effectiveness and safety of apixaban, LMWH, and warfarin among high-risk subgroups of VTE patients with active cancer.
Cohen AT; Keshishian A; Lee T; Rosenblatt L; Hlavacek P; Sah J; Luo X
Curr Med Res Opin; 2021 Sep; 37(9):1467-1482. PubMed ID: 34030541
[TBL] [Abstract][Full Text] [Related]
20. Survival outcomes with warfarin compared with direct oral anticoagulants in cancer-associated venous thromboembolism in the United States: A population-based cohort study.
Khan AM; Chiasakul T; Redd R; Patell R; McCarthy EP; Neuberg D; Zwicker JI
PLoS Med; 2022 May; 19(5):e1004012. PubMed ID: 35613184
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]